Originally published as JCO Early Release 10.1200/JCO.2004.00.3335 on January 9 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weinberger, P. M. Articles by Psyrri, A. Search for Related Content PubMed PubMed Citation Articles by Weinberger, P. M. Articles by Psyrri, A.

Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis

From the Departments of Medical Oncology, Otolaryngology, Therapeutic Radiology, Pathology, and Comparative Anatomy, Yale University School of Medicine, New Haven, CT

Address reprint requests to Amanda Psyrri, MD, Yale Cancer Center, PO Box 208032, New Haven, CT 06520; e-mail: diamando.psyrri{at}yale.edu

PURPOSE: We sought to determine the prevalence of biologically relevant human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OSCC). Retinoblastoma (Rb) downregulation by HPV E7 results in p16 upregulation. We hypothesized that p16 overexpression in OSCC defines HPV-induced tumors with favorable prognosis.

METHODS: Using real-time polymerase chain reaction for HPV16, we determined HPV16 viral load in a cohort of 79 OSCCs annotated with long-term patient follow-up. A tissue microarray including these cases was also analyzed for p53, p16, and Rb utilizing in situ quantitative protein expression analysis. Seventy-seven tumors were classified into a three-class model on the basis of p16 expression and HPV-DNA presence: class I, HPV–, p16 low; class II, HPV+, p16 low; and class III, HPV+, p16 high.

RESULTS: Sixty-one percent of OSCCs were HPV16+; HPV status alone was of no prognostic value for local recurrence and was barely significant for survival times. Overall survival was improved in class III (79%) compared with the other two classes (20% and 18%; P = .0095). Disease-free survival for the same class was 75% versus 15% and 13% (P = .0025). The 5-year local recurrence was 14% in class III versus 45% and 74% (P = .03). Only patients in class III had significantly lower p53 and Rb expression (P = .017 and .001, respectively). Multivariable survival analysis confirmed the prognostic value of the three-class model.

CONCLUSION: Using this system for classification, we define the molecular profile of HPV+ OSCC with favorable prognosis, namely HPV+/p16 high (class III). This study defines a novel classification scheme that may have value for patient stratification for clinical trials testing HPV-targeted therapies.

Supported by the Yale University Institutional Startup Fund (A.P.), the Virginia Alden Wright Fund (C.S.), and the Doris Duke Charitable Foundation (P.M.W.).

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				B. Singh and D. G. Pfister Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge? J. Clin. Oncol., July 1, 2008; 26(19): 3114 - 3116. [Full Text] [PDF]

				M. L. Gillison, G. D'Souza, W. Westra, E. Sugar, W. Xiao, S. Begum, and R. Viscidi Distinct Risk Factor Profiles for Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Cancers J Natl Cancer Inst, March 19, 2008; 100(6): 407 - 420. [Abstract] [Full Text] [PDF]

				C. Fakhry, W. H. Westra, S. Li, A. Cmelak, J. A. Ridge, H. Pinto, A. Forastiere, and M. L. Gillison Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial J Natl Cancer Inst, February 20, 2008; 100(4): 261 - 269. [Abstract] [Full Text] [PDF]

				A. K. Chaturvedi, E. A. Engels, W. F. Anderson, and M. L. Gillison Incidence Trends for Human Papillomavirus-Related and -Unrelated Oral Squamous Cell Carcinomas in the United States J. Clin. Oncol., February 1, 2008; 26(4): 612 - 619. [Abstract] [Full Text] [PDF]

				W. H. Westra, J. M. Taube, M.L. Poeta, S. Begum, D. Sidransky, and W. M. Koch Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive p53 Gene Mutations in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., January 15, 2008; 14(2): 366 - 369. [Abstract] [Full Text] [PDF]

				N. Choong and E. Vokes Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53. [Abstract] [Full Text] [PDF]

				S. Begum, M. L. Gillison, T. L. Nicol, and W. H. Westra Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., February 15, 2007; 13(4): 1186 - 1191. [Abstract] [Full Text] [PDF]

				M. L. Gillison Human Papillomavirus and Prognosis of Oropharyngeal Squamous Cell Carcinoma: Implications for Clinical Research in Head and Neck Cancers J. Clin. Oncol., December 20, 2006; 24(36): 5623 - 5625. [Full Text] [PDF]

				K. Strati, H. C. Pitot, and P. F. Lambert Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model PNAS, September 19, 2006; 103(38): 14152 - 14157. [Abstract] [Full Text] [PDF]

				C. Fakhry and M. L. Gillison Clinical Implications of Human Papillomavirus in Head and Neck Cancers J. Clin. Oncol., June 10, 2006; 24(17): 2606 - 2611. [Abstract] [Full Text] [PDF]